课题基金 / 基金详情

Validation of a novel biomarker classifier that predicts radiation response following breast-conserving surgery for ductal carcinoma in situ (DCIS)

Validation of a novel biomarker classifier that predicts radiation response following breast-conserving surgery for ductal carcinoma in situ (DCIS)
验证一种新型生物标志物分类器，可预测导管原位癌 (DCIS) 保乳手术后的放射反应
批准号：
470541
负责人：
Rakovitch Eileen
金额：
$144.34万
依托单位：
Sunnybrook Research Institute (Toronto, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-09-01 至 2026-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=470541&lang=en
关键词：
Biomarkers Breast Cancer Dcis Ductal Carcinoma In Situ Progression Radiotherapy Recurrence

项目摘要

项目成果

Rakovitch Eileen的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Ductal carcinoma in situ (DCIS) is a non-invasive type of breast cancer. Treatment of DCIS is recommended as some DCIS tumors can develop into invasive breast cancer. Most women are treated with breast-conserving surgery followed by breast radiation (RT)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prospective Evaluation of Breast-Conserving Surgery Alone in Low Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined with Clinico-Pathological Features
  • 批准号：
    420916
  • 项目类别：
    Operating Grants
  • 资助金额：
    $90.0万
  • 财政年份：
    2020
  • 负责人：
    Rakovitch Eileen
  • 依托单位：
    Ontario Clinical Oncology Group
DCIS-Precise: A Genomics-Driven Model for Predicting DCIS Response to Radiation
海外基金